Roche’s Oncology Pipeline Shows Promise in Treating Aggressive Brain Metastases
Roche’s trastuzumab, capecitabine, and tucatinib combo more than doubled median survival to 10 months in HER2+ breast cancer…
Neurological Pipeline Progress Offers Long-Term Promise for Roche
Neurological, Pipeline
22.03.2026 – 06:25:56 | boerse-global.de
Roche presents promising Alzheimer’s & Parkinson’s data,…